By SYNGAP1 Foundation
Washington, DC 20003
To be determined
THIS EVENT CLOSES AT 100 IN-PERSON PARTICIPANTS...BUY YOUR TICKET TO ENSURE A RESERVATION
Room Block Closes March 24, 2023
In the Spring of 2023, we are planning the first SYNGAPI Industry Round Table. This in-person event will foster discussion with a focus on the outcomes and results of the Externally Led Patient-Focused Drug Development Meeting, SYNGAPI: Voices of the Caregiver and Patient Report, held in November 2020 held with support/in conjunction with the U.S. Food and Drug Administration (FDA). It is an exclusive opportunity for industry members focusing on drug development for SYNGAPI and interest in related overlapping neurological disorders linked to SYNGAPI, such as Alzheimer's, Parkinson's, and associated mental illnesses and disorders.
Our goal is to capture the interest of leading pharmaceutical companies in drug development to broaden drug development programs influencing the investigation and potential overlapping mechanisms in SYNGAP1 symptomology. And repurposing drugs based on the physiological symptoms of the disorder while paving a path forward to helping find treatments for the SYNGAP1 Community.
This meeting aims to educate and inspire pharmaceutical companies, biotech, and start-ups to become invested in developing therapeutics. This forum will provide valuable information and encourage new research collaborations around therapies while discussing optimal, efficient paths forward, targeting meaningful endpoints and outcome measures for individuals with SYNGAP1 mutations while investigating overlap into more common diseases linked to the SYNGAP1 protein.
We believe in understanding how the SYNGAP1 gene and its respective cell protein, SynGAP, function at a cellular level by uncovering the common physiological symptoms that SYNGAP1 mutations exhibit in people to find treatments open doors to discoveries that will lead to treatments for other related neurological disorders.
Partnering with patient advocacy communities is one of the most effective ways for healthcare industry members to engage and connect with their primary audience robustly.
2023 SYNGAP1 Industry Round Table ~ Washington DC
Start Date: Monday, April 17, 2023
End Date: Tuesday, April 18, 2023
Last Day to Book: Friday, March 17, 2023
Hotel(s) offering your special group rate:
BOOK HERE:
Moderator: Matt Toresco
8:00 AM - Registration and Light Continental Breakfast
8:15 AM - Welcome and Opening Remarks - Event Host
The Honorable Joseph R. Barton, Partner, Barton-Albright Strategies, U.S. House of Representatives, 1985 – 2019; and Chair, House Energy and Commerce Committee, 2003 – 2006; 6 Years - Health Subcommittee Oversight Committee
8:25 AM - Keynote Introduction – Patient Advocacy -- Ensuring that ‘P’ Value stands for ‘Patient’ Annie Kennedy; Chief of Policy, Advocacy, & Patient Engagement; EveryLife Foundation for Rare Diseases
8:45 AM Industry Perspective - Therapeutically targeting KCC2 to restore excitation/inhibition imbalance pathologies in neurodevelopmental disorders.
Dr. Shane Hegarty; Chief Scientific Officer; Founder and IP Inventor at AXONIS Therapeutics (Virtual)
9:05 AM - Clinical Finding and Potential Clinical Trial Measures (Topic TBD)
Constance Hicks-Smith, Ph.D., MD~ Kennedy Krieger Institute
9:30 AM - Clinical Findings and Potential Clinical Trial Measures (Topic TBD)
Jimmy Holder, Ph.D., MD ~ Texas Children's Hospital/Baylor College of Medicine
9:50 AM - Break
10:00 AM - Cognition and Behavior in SYNGAP1
Andrew Stanfield, Ph.D., MD~ Edinburgh University/Patrick Wild Center (Virtual)
10:20 AM - Industry Prospective - Clinical Trial Design (TBA)
10:40 AM - SYNGAP1 (MRDS) Natural History Study & Registry & Insights EL-PFDD Report
Monica Dudley-Weldon, MSL ~ CEO ~ SYNGAP1 Foundation
11:00 AM - Speaker Panel Discussion: Designing the Best Clinical Trials
Moderator: Matt Toresco
Begin 11:30 AM -Q&A Discussion
11:50 AM - Conclusion and Summary
Matt Toresco, Board Member SYNGAP1 Foundation
12:00 PM - 1:00 PM - Networking Lunch